ProKidney Corp

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

• ↑Analysts’ $10 target implies >500% upside from $1.61
• ↑Q1 2026 narrow EPS beat validates rilparencel’s efficacy momentum
• ↓Clinical stage with no approved therapies limits revenue prospects